30 NOV 2023 · In this episode of The Onco’Zine Brief Peter Hofland talks with Stephen Spellman. Stephen Spellman is Vice President and Senior Scientific Director at https://bethematch.org/ and the Center for International Blood & Marrow Transplant Research (https://cibmtr.org/). Hofland and Spellman talk about the outcomes of a study published in https://ashpublications.org/bloodadvances, the journal of the https://www.hematology.org/. [1] The article discusses the impact of cryopreservation of hematopoietic cell grafts on overall survival (OS) and other outcomes within 1 year after hematopoietic cell transplantation. At the beginning of the COVID-19 pandemic the National Marrow Donor Program as together with other national and international donor registries mandated the cryopreservation of hematopoietic cell grafts during the first 6 months of the pandemic because of patient and donor safety concerns. The reason was that during the early days of the pandemic, delivery of donor products after patient conditioning could not be guaranteed. This was, in part, caused by logistical complexities including travel bans, flight delays and cancellations, rerouting of couriers – as well as closed border crossings… In addition, donors were at risk of being infected with the SARS CoV-2 Virus, the virus that causes COVID-19, which, in turn, resulted in last-minute cancellations of graft collection. To solve the pandemic-related logistical problems, the authors of the study conclude that cryopreservation should be considered a method to eliminate the potential risks with the use of fresh donor graft products or when fresh grafts are not available. But what was the impact of cryopreservation on patients receiving hematopoietic cell transplantation compared to the effects among patients receiving fresh donor products? Was there a difference in overall survival, disease free survival, or disease recurrence? Was there a risk in Graft vs Host Disease? In this episode of The Onco’Zine Brief Hofland and Spellman talk about this and more. Reference [1] Devine SM, Bo-Subait S, Kuxhausen M, Spellman SR, Bupp C, Ahn KW, Stefanski HE, Auletta JJ, Logan BR, Shaw BE. Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic. Blood Adv. 2023 Oct 10;7(19):5982-5993. doi: 10.1182/bloodadvances.2023009786. PMID: 37036959; PMCID: PMC10580174. [https://ashpublications.org/bloodadvances/article/7/19/5982/495268/Clinical-impact-of-cryopreservation-of-allogeneic][https://pubmed.ncbi.nlm.nih.gov/37036959/] About The Onco'Zine Brief The Onco’Zine Brief is developed in collaboration with our http://www.oncozine.com, where you can find additional information and the latest news about cancer diagnosis and treatment, and cancer prevention. The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit, visit our https://www.patreon.com/theoncozinebrief page, or https://www.oncozine.com/advertisement-sponsorship-options/. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. Support for The Onco’Zine Brief comes from thehttp://www.oncologydirectory.com and from listeners like you. Funding is also provided by http://www.javaoriginalcoffee.comand http://www.roastmasterz.com.

5 OCT 2023 · In a new episode of https://www.spreaker.com/user/7078249/tob-itunes-full-show-sonalasense-sdt, Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph.D, President and Chief Executive Officer of https://www.sonalasense.com/. SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive therapy option using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS) to treat and eradicate deadly cancers like High-Grade Gliomas (HGG) that typically require debilitating brain surgery that often leads to tumor recurrence. SonALAsense’s SDT uses SONALA-001, a proprietary formulation of aminolevulinic acid (ALA), to disrupt heme metabolism in tumor cells, increasing production of protoporphyrin, a heme precursor. From there, energy from focused ultrasound excites protoporphyrin molecules, which produce reactive oxygen species that destroy cancer cells. https://www.spreaker.com/user/7078249/tob-itunes-full-show-sonalasense-sdthttps://link.springer.com/article/10.1007/s11060-023-04269-8on the first DIPG patient treated with SONALA-001 in the Journal of Neuro-Oncology; a major milestone for this deadly and understudied childhood disease. [1] Hofland, Benaim and De Souza talk about new technologies in the treatment of difficult to treat cancers. Reference [1] Syed HR, Kilburn L, Fonseca A, Nazarian J, Oluigbo C, Myseros JS, Packer RJ, Keating RF. First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication. J Neurooncol. 2023 Apr;162(2):449-451. doi: 10.1007/s11060-023-04269-8. Epub 2023 Apr 12. PMID: 37046110. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit, visit our https://www.patreon.com/theoncozinebrief page, or https://www.oncozine.com/advertisement-sponsorship-options/. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com/ and https://roastmasterz.com/.

28 SEP 2023 · In a new episode of https://www.spreaker.com/user/7078249/tob-itunes-full-be-the-match, Peter Hofland talks with Jeffery Auletta, MD is Senior Vice President, Patient Outcomes and Experience, National Marrow Donor Program® (NMDP)/Be The Match®. https://bethematch.org/ is a global leader in bone marrow transplantation. The organization conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global network. Unmet medical need Every three or four minutes, someone in the United States is diagnosed with a hematological malignancy such as leukemia, a cancer of blood-forming tissues, including bone marrow. For many patients, their only hope for a cure is a stem cell transplant. In the program, Hofland and Auletta talk about these unmet medical needs and about the new developments exploring the use of a standardized method of assessing measurable residual disease (MRD) before allogeneic hematopoietic stem cell transplantation (HCT) in patients with leukemia and how this provides valuable insight into MRD as a predictive tool to inform HCT decisions and individualize treatment to improve outcomes. Hofland and Auletta also talk about the importance of people to join and register with Be The Match® as a bone marrow donor to bring hope to people in need. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit, visit our https://www.patreon.com/theoncozinebrief page, or https://www.oncozine.com/advertisement-sponsorship-options/. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com/ and https://roastmasterz.com/.

14 AUG 2023 ·  In a new episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia. Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy. Head and Neck Cancer According to the American Cancer Society, Head and neck cancer accounts for about 4% of all cancers in the United States. In the United States in 2023, an estimated 67,000 people will be diagnosed with head and neck cancer and about 15,000 patients are expected to die of the disease. Today, many cancers of the head and neck can be cured, especially if they are found early. And while eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important. Beyond Current Treatment Photoimmunotherapy is a recently developed hybrid cancer therapy to treat diseases by linking specific antibodies with photosensitizers to form photoimmunoconjugates. But let’s go back to the beginning. Surgery, radiation, and chemotherapy have dominated the treatment of oncologic. These therapies aim to eradicate cancer cells but, unfortunately, do that at the expense of normal, or healthy cells/ In turn, this can lead to severe and sometimes lethal side-effects. Overall, the success of surgery, radiation and chemotherapy is measured by what we call a ‘therapeutic index.’ This ‘therapeutic index’ compares the potential benefits of treatment to the potential risks associated with treatment. Unfortunately, the unintended, off-target side effects of these therapies can have profound effects on the health-related quality of life of patients. For example, both radiation and chemotherapy sometimes preferentially kill lymphocytes much earlier than cancer cells because of the increased radiation sensitivity and high proliferation rate of lymphocytes, potentially leading to dose-limiting toxicity for some chemotherapy regimens. To find a solution, researchers have developed new therapeutic strategies. And while these therapies have created an exciting new direction for the treatment of cancer therapy, there remain limitation to these novel approaches. Now, in theory, the perfect cancer therapy would both directly destroy cancer cells to minimize residual cancer cells as well as activate the local host immune response to wipe out remaining cancer cells. And while such a therapy would be highly selective for cancer cells but have minimal or no off-target effects in the tumor microenvironment. Photoimmunotherapy And that’s where photoimmunotherapy comes in. Photoimmunotherapy, designed to selectively destroy target cells. The therapy that induces direct cancer killing via immunogenic cell death, thus activating the anti-cancer immune system locally in the tumor microenvironment. The specificity of this approach comes from the antibody that is designed to target an expressed antigen on the tumor surface and is conjugated to the photo-activating chemical. The safety of Photoimmunotherapy is based on the fact that the antibody–photo-absorber conjugate predominantly binds to specifically targeted cancer cells and that it is only activated in areas exposed to Near-infrared light at a specific activating wavelength. By choosing tumor-specific antigens, this therapy specifically destroys cancer cells while not or only minimally harming any adjacent normal or healthy cells, particularly tumor-infiltrating immune T cells or blood vessels. Furthermore, the photo-activating chemical is a water-soluble photo-absorbing dye without cytotoxic properties of its own. Clinical studies have shown that this combination can enhance the immune response, and, as a result, have a good effect on the treatment of residual tumor and metastatic cancer. The first human study of a Photoimmunotherapy was with ASP-1929 – which is being developed by Rakuten Medical to treat inoperable head and neck cancer. ASP-1929 is a conjugate of cetuximab, an anti-EGFR antibody plus the photo-absorber called IR700. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit, visit our https://www.patreon.com/theoncozinebrief page, or https://www.oncozine.com/advertisement-sponsorship-options/. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com/ and https://roastmasterz.com/. . Clinical trials ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy - https://classic.clinicaltrials.gov/ct2/show/NCT03769506 ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases - https://clinicaltrials.gov/study/NCT05265013 ASP-1929 Photoimmunotherapy (PIT) Study in in Patients With Recurrent Head/​Neck Cancer - https://clinicaltrials.gov/study/NCT05182866 An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors - https://clinicaltrials.gov/study/NCT04305795 Reference [1] Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol. 2021 Jan 1;33(1):7-15. doi: 10.1093/intimm/dxaa037. PMID: 32496557; PMCID: PMC7771006. [2] Kobayashi H, Griffiths GL, Choyke PL. Near-Infrared Photoimmunotherapy: Photoactivatable Antibody-Drug Conjugates (ADCs). Bioconjug Chem. 2020 Jan 15;31(1):28-36. doi: 10.1021/acs.bioconjchem.9b00546. Epub 2019 Sep 13. PMID: 31479610; PMCID: PMC7414968. Feature Image Courtesy: © 2020 U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Used with permission. =====

16 APR 2023 ·  In this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer. First, Hofland talks with Christopher Heery, MD. Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, including, but not limited to PD-L1 inhibitors, therapeutic cancer vaccines, immune suppressor modulator, adoptive NK cells, and other therapeutics. As the chief medical officer at https://www.arcellx.com/, he is responsible for medical oversight, clinical strategy, medical affairs, and regulatory strategy for the company’s pipeline of novel – investigational drug. In the second half of the program, Hofland talks with Srdan Verstovsek, Dr Srdan Verstovsek, MD, PhD., a Medical Oncologist and Professor in the https://www.mdanderson.org/research/departments-labs-institutes/programs-centers/clinical-research-center-for-myeloproliferative-neoplasms/faculty-staff.html at https://www.mdanderson.org/, about some of the developments in the treatment of myeloproliferative neoplasm, which are types of blood cancer that begin with an abnormal mutation or change, in a stem cell in the bone marrow. These change leads to an overproduction of any combination of white cells, red blood cells and platelets – and results in a number of diseases, including: - Essential Thrombocythemia (ET) Is a rare blood disease in which the bone marrow produces too many platelets; - Myelofibrosis, a rare disorder in which abnormal blood cells and fibers build up in the bone marrow; - Polycythemia Vera (PV) – a disease in which too many red blood cells are made in the bone marrow and, in many cases, the numbers of white blood cells and platelets are also elevated.  In a new episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia. Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy. Head and Neck Cancer According to the American Cancer Society, Head and neck cancer accounts for about 4% of all cancers in the United States. In the United States in 2023, an estimated 67,000 people will be diagnosed with head and neck cancer and about 15,000 patients are expected to die of the disease. Today, many cancers of the head and neck can be cured, especially if they are found early. And while eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important. Beyond Current Treatment Photoimmunotherapy is a recently developed hybrid cancer therapy to treat diseases by linking specific antibodies with photosensitizers to form photoimmunoconjugates. But let’s go back to the beginning. Surgery, radiation, and chemotherapy have dominated the treatment of oncologic. These therapies aim to eradicate cancer cells but, unfortunately, do that at the expense of normal, or healthy cells/ In turn, this can lead to severe and sometimes lethal side-effects. Overall, the success of surgery, radiation and chemotherapy is measured by what we call a ‘therapeutic index.’ This ‘therapeutic index’ compares the potential benefits of treatment to the potential risks associated with treatment. Unfortunately, the unintended, off-target side effects of these therapies can have profound effects on the health-related quality of life of patients. For example, both radiation and chemotherapy sometimes preferentially kill lymphocytes much earlier than cancer cells because of the increased radiation sensitivity and high proliferation rate of lymphocytes, potentially leading to dose-limiting toxicity for some chemotherapy regimens. To find a solution, researchers have developed new therapeutic strategies. And while these therapies have created an exciting new direction for the treatment of cancer therapy, there remain limitation to these novel approaches. Now, in theory, the perfect cancer therapy would both directly destroy cancer cells to minimize residual cancer cells as well as activate the local host immune response to wipe out remaining cancer cells. And while such a therapy would be highly selective for cancer cells but have minimal or no off-target effects in the tumor microenvironment. Photoimmunotherapy And that’s where photoimmunotherapy comes in. Photoimmunotherapy, designed to selectively destroy target cells. The therapy that induces direct cancer killing via immunogenic cell death, thus activating the anti-cancer immune system locally in the tumor microenvironment. The specificity of this approach comes from the antibody that is designed to target an expressed antigen on the tumor surface and is conjugated to the photo-activating chemical. The safety of Photoimmunotherapy is based on the fact that the antibody–photo-absorber conjugate predominantly binds to specifically targeted cancer cells and that it is only activated in areas exposed to Near-infrared light at a specific activating wavelength. By choosing tumor-specific antigens, this therapy specifically destroys cancer cells while not or only minimally harming any adjacent normal or healthy cells, particularly tumor-infiltrating immune T cells or blood vessels. Furthermore, the photo-activating chemical is a water-soluble photo-absorbing dye without cytotoxic properties of its own. Clinical studies have shown that this combination can enhance the immune response, and, as a result, have a good effect on the treatment of residual tumor and metastatic cancer. The first human study of a Photoimmunotherapy was with ASP-1929 – which is being developed by Rakuten Medical to treat inoperable head and neck cancer. ASP-1929 is a conjugate of cetuximab, an anti-EGFR antibody plus the photo-absorber called IR700. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit, visit our https://www.patreon.com/theoncozinebrief page, or https://www.oncozine.com/advertisement-sponsorship-options/. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com/ and https://roastmasterz.com/.

14 MAR 2023 · Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells. Antibody-drug conjugates consist of three parts: - an antibody specific to the target associated antigen, - a payload (sometimes calles a warhead) designed to kill target cancer cells, and - a chemical linker specifically designed to attach or link the payload to the antibody. Today, antibody-drug conjugates have widespread treatment potential in obcology and hematology, and beyond. However, safe manufacturing of these highly potent drugs requires also requires a highly skilled capable team of experts in well-controlled manufacturing facilities. In this episode of the Onco’Zine Brief, produced in collaboration with https://www.adcreview.com, Peter Hofland talks with Dr. Matthias Bucerius. Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations. The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates. Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies. What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs. This combination makes these agents uniquely targetable therapies. And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit, or visit our https://www.patreon.com/theoncozinebrief page. For more information about cancer and cancer treatments, visit our online journal https://www.oncozine.com/ - To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com/ – the home of artisan roasted coffee and https://roastmasterz.com.

17 FEB 2023 · In December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results. In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from these studies may have. First, Hofland talks with Thomas G. Martin, MD. Martin is the Associate Director of the University of California San Francisco Myeloma Program and Director of the Unrelated Donor Transplantation program for adults at UCSF Medical Center. Martin's research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants, and he is involved in efforts to improve outcomes for patients who have transplants from unrelated donors. In this episode Hofland and Martin talk about updated results from a Phase 1b expansion study evaluating subcutaneous administration of Isatuximab-irfc (https://www.sarclisahcp.com/; Sanofi) by an on-body delivery system in combination with pomalidomide (https://www.pomalysthcp.com/; Bristol-Myers Squibb Company) and dexamethasone in patients with relapsed/refractory multiple myeloma. How does subcutaneous delivery vs. intravenous administration of Isatuximab benefits patients? Hofland and Martin also talk about the results of a Subgroup Analysis of the IKEMA trial. Then, With Monica Soni, MD, Director of Specialty Care for the Los Angeles County Department of Health Services, the second-largest municipal health system in the United States. She is also an assistant clinical professor within the UCLA Department of Medicine. Soni is commitment to improving quality, equity and affordability in health care. In this episode Hofland and Soni talks about the results of a study in which the investigators looked at the utilization of bone-modifying agents (BMA) in the treatment of multiple myeloma, particularly among Medicaid patients. What invesrigatriors found was shocking! About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit202122/, visit https://www.patreon.com/theoncozinebrief at or https://www.oncozine.com/advertisement-sponsorship-options/. For more information about cancer and cancer treatments, visit our online journal https://www.oncozine.com/ To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com/ – the home of artisan roasted coffee. Clinical trial Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA) -https://clinicaltrials.gov/ct2/show/NCT03275285

17 JAN 2023 · In the 100th episode of the Onco’Zine Brief, Peter Hofland, Ph.D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match. In the program today Hofland and Spellman talk about bone-marrow transplants. The likelihood of finding a fully matched unrelated donor for a patient who needs a bone marrow transplantvaries greatly depending on a patient’s ethnic background, and that ethnically diverse patients have – historically – been at a disadvantage. However, new research shows that when donor registry models are expanded to include mismatched unrelated donors, finding access for patients may greatly improve.[1] Based on this understanding, Spellman believes that mismatched unrelated donors hold the key to erasing the gap in donor availability and deliver allogeneic hematopoietic cell transplantation (HCT) to all patient populations. For more information about the Center for International Blood and Marrow Transplant Research, please http://www.CIBMTR.org. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit202122/, visit https://www.patreon.com/theoncozinebrief at or https://www.oncozine.com/advertisement-sponsorship-options/. For more information about cancer and cancer treatments, visit our online journal https://www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com – the home of artisan roasted coffee. Reference [1] Spellman S. Is finding a Donor for All in Need of Allogeneic HCT Possible? New Modeling Says Yes – Onco’Zine on September 5, 2022. [https://www.oncozine.com/is-finding-a-donor-for-all-in-need-of-allogeneic-hct-possible-new-modeling-says-yes/]

29 NOV 2022 · In this edition of The Onco'Zine Brief, Peter Hofland, Ph.D, talks with Susanna F. Greer, Ph.D. the Chief Scientific Officer of the V Foundation. In her role, Dr. Greer is a visionary ambassador of the V Foundation, who works with the foundation’s Scientific Advisory Committee to steer funding to the most promising research opportunities. An accomplished strategist, she develops and articulates priorities to enhance the V Foundation’s research portfolio, gifts, grants, and sponsorships that advance the V Foundation’s distinctive brand of cutting-edge and disruptive research. The V Foundation was founded in 1993 by ESPN and the late Jim Valvano, legendary NC State University basketball coach and ESPN commentator. The mission of the V Foundation is to funds game-changing research and all-star scientists to accelerate Victory Over Cancer® and save lives. Today the V Foundation funds research for all cancer types, at leading cancer centers and research facilities nationwide. The organization awards 100% of direct donations to cancer research and programs. The Foundation’s endowment covers administrative expenses. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit202122/, visit https://www.patreon.com/theoncozinebrief at or https://www.oncozine.com/advertisement-sponsorship-options/. For more information about cancer and cancer treatments, visit our online journal https://www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com – the home of artisan roasted coffee.

27 OCT 2022 · Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes. In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Sean P. Bohen, MD, Ph.D., the president and Chief Executive Officer of Olema Therapeutics. Olema Terapeutics is developing new treatment options designed to improve outcomes for women with metastatic breast cancer. The company’s lead investigational drug is OP-1250. This drug is a is a novel agent with combined activity as both an advanced complete estrogen receptor antagonist, and a selective estrogen receptor degrader. This approach is expected to drive deeper, more durable responses than currently available therapies. OP-1250 is currently in development as a treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), in both monotherapy and combination settings. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit202122/, visit https://www.patreon.com/theoncozinebrief at or https://www.oncozine.com/advertisement-sponsorship-options/. For more information about cancer and cancer treatments, visit our online journal https://www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com – the home of artisan roasted coffee. Clinical trials - Phase 1b Combo w/ Ribociclib and Alpelisib | NCT05508906 - A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients - NCT05266105 -A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer - NCT04505826